Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors
- PMID: 40175553
- PMCID: PMC12188471
- DOI: 10.1038/s41586-025-08813-6
Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors
Erratum in
-
Publisher Correction: Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors.Nature. 2025 Oct;646(8087):E33. doi: 10.1038/s41586-025-09671-y. Nature. 2025. PMID: 41023408 No abstract available.
Abstract
Psilocybin is a serotonergic psychedelic with therapeutic potential for treating mental illnesses1-4. At the cellular level, psychedelics induce structural neural plasticity5,6, exemplified by the drug-evoked growth and remodelling of dendritic spines in cortical pyramidal cells7-9. A key question is how these cellular modifications map onto cell-type-specific circuits to produce the psychedelics' behavioural actions10. Here we use in vivo optical imaging, chemogenetic perturbation and cell-type-specific electrophysiology to investigate the impact of psilocybin on the two main types of pyramidal cells in the mouse medial frontal cortex. We find that a single dose of psilocybin increases the density of dendritic spines in both the subcortical-projecting, pyramidal tract (PT) and intratelencephalic (IT) cell types. Behaviourally, silencing the PT neurons eliminates psilocybin's ability to ameliorate stress-related phenotypes, whereas silencing IT neurons has no detectable effect. In PT neurons only, psilocybin boosts synaptic calcium transients and elevates firing rates acutely after administration. Targeted knockout of 5-HT2A receptors abolishes psilocybin's effects on stress-related behaviour and structural plasticity. Collectively, these results identify that a pyramidal cell type and the 5-HT2A receptor in the medial frontal cortex have essential roles in psilocybin's long-term drug action.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: A.C.K. has been a scientific advisor or consultant for Boehringer Ingelheim, Empyrean Neuroscience, Freedom Biosciences and Xylo Bio. A.C.K. has received research support from Intra-Cellular Therapies. The other authors declare no competing interests.
Update of
-
Pyramidal cell types and 5-HT2A receptors are essential for psilocybin's lasting drug action.bioRxiv [Preprint]. 2024 Nov 3:2024.11.02.621692. doi: 10.1101/2024.11.02.621692. bioRxiv. 2024. Update in: Nature. 2025 Jun;642(8067):411-420. doi: 10.1038/s41586-025-08813-6. PMID: 39554087 Free PMC article. Updated. Preprint.
References
MeSH terms
Substances
Grants and funding
- R01 NS133434/NS/NINDS NIH HHS/United States
- T32 NS041228/NS/NINDS NIH HHS/United States
- R00 NS114166/NS/NINDS NIH HHS/United States
- R01 MH121848/MH/NIMH NIH HHS/United States
- F30 MH129085/MH/NIMH NIH HHS/United States
- F30 DA059437/DA/NIDA NIH HHS/United States
- S10 OD032251/OD/NIH HHS/United States
- R01 MH128217/MH/NIMH NIH HHS/United States
- R01 DA059378/DA/NIDA NIH HHS/United States
- T32 GM007205/GM/NIGMS NIH HHS/United States
- U01 NS128660/NS/NINDS NIH HHS/United States
- R01 MH137047/MH/NIMH NIH HHS/United States
- S10 RR025502/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
